Premium
Outcome in Carcinoma in situ of Bladder Treated with Intravesical Bacille Calmette‐Guérin
Author(s) -
HARLAND S. J.,
CHARIG C. R.,
HIGHMAN W.,
PARKINSON M. C.,
RIDDLE P. R.
Publication year - 1992
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1992.tb15730.x
Subject(s) - carcinoma in situ , medicine , urology , bladder cancer , carcinoma , oncology , cancer
Summary— Fifty‐three patients with carcinoma in situ of the bladder were treated with Evans strain BCG given intravesically. Complete remission was achieved after either one or two 6‐weekly courses in 53% of patients. The median duration of remission was 32 months. Treatment‐related bladder symptoms were minor during the first course, more severe during the second. There was no relation between severity of symptoms and likelihood of response. With a median follow‐up of 32 months, disease progression has occurred in 10% of complete responders, whereas failure to respond on either cystoscopic, histological or cytological grounds was associated with a 48% progression rate. Although intravesical BCG produces impressive responses in carcinoma in situ of the bladder, managed conservatively the condition remains a dangerous one.